DK1453844T3 - Anvendelse af glycosider af mono- og diacylglycerol som anti-inflammatoriske midler - Google Patents

Anvendelse af glycosider af mono- og diacylglycerol som anti-inflammatoriske midler

Info

Publication number
DK1453844T3
DK1453844T3 DK02803339.7T DK02803339T DK1453844T3 DK 1453844 T3 DK1453844 T3 DK 1453844T3 DK 02803339 T DK02803339 T DK 02803339T DK 1453844 T3 DK1453844 T3 DK 1453844T3
Authority
DK
Denmark
Prior art keywords
diacylgylcerol
glycosides
mono
application
inflammatory agents
Prior art date
Application number
DK02803339.7T
Other languages
Danish (da)
English (en)
Inventor
Erik Larsen
Arsalan Kharazmi
Soren Brogger Christensen
Lars Porskjaer Christensen
Kirsten Brandt
Original Assignee
Univ Aarhus
H S Rigshospitalet
Univ Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus, H S Rigshospitalet, Univ Copenhagen filed Critical Univ Aarhus
Application granted granted Critical
Publication of DK1453844T3 publication Critical patent/DK1453844T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
DK02803339.7T 2001-11-21 2002-11-21 Anvendelse af glycosider af mono- og diacylglycerol som anti-inflammatoriske midler DK1453844T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33208401P 2001-11-21 2001-11-21
US34160901P 2001-12-18 2001-12-18
US35839102P 2002-02-22 2002-02-22
PCT/DK2002/000783 WO2003043613A2 (en) 2001-11-21 2002-11-21 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
DK1453844T3 true DK1453844T3 (da) 2014-02-10

Family

ID=27406836

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02803339.7T DK1453844T3 (da) 2001-11-21 2002-11-21 Anvendelse af glycosider af mono- og diacylglycerol som anti-inflammatoriske midler

Country Status (9)

Country Link
US (2) US7084122B2 (enExample)
EP (1) EP1453844B1 (enExample)
JP (2) JP4716655B2 (enExample)
CN (1) CN100469784C (enExample)
AU (1) AU2002366210A1 (enExample)
DK (1) DK1453844T3 (enExample)
NO (1) NO334587B1 (enExample)
PL (2) PL393941A1 (enExample)
WO (1) WO2003043613A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
JP3914519B2 (ja) * 2003-06-06 2007-05-16 株式会社スピルリナ研究所 グリセロ糖脂質化合物を含有してなるリパーゼ活性阻害剤
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
KR101245440B1 (ko) * 2003-09-12 2013-03-19 액세스 비지니스 그룹 인터내셔날 엘엘씨 사이토킨 조절물질 및 관련된 용도
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
JP3790767B2 (ja) * 2004-06-30 2006-06-28 森下仁丹株式会社 脂肪代謝改善組成物
US20070269540A1 (en) * 2006-05-16 2007-11-22 Morishita Jintan Co., Ltd. Fat metabolism improving agent
JP4866067B2 (ja) * 2005-11-22 2012-02-01 株式会社ファンケル メラニン産生抑制剤
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
ATE524483T1 (de) * 2006-07-03 2011-09-15 Hyben Vital Licens Aps Verfahren zur herstellung eines glykosids eines mono- oder diacylglyzerinprodukts aus einem pflanzlichen material
US7547455B2 (en) * 2006-09-20 2009-06-16 Academia Sinica Cancer and inflammatory disorder treatment
KR100772078B1 (ko) 2006-11-07 2007-10-31 한국기초과학지원연구원 갈조류 지충이로부터 분리된 신규모노갈락토실디아실글리세롤 화합물
JPWO2008108001A1 (ja) * 2007-03-02 2010-06-10 株式会社東洋新薬 ガラクト脂質
HRP20150593T1 (hr) * 2007-12-21 2015-07-31 Finzelberg Gmbh & Co. Kg Pripravci s ekstraktima šipka i postupak proizvodnje ekstrakta šipka
NZ567712A (en) * 2008-04-24 2010-11-26 Fonterra Cooperative Group Ltd Compositions and methods for maintaining bone health or reducing bone loss
US9173912B2 (en) 2008-05-06 2015-11-03 Finzelberg Gmbh & Co. Kg Cistus extract containing enriched secondary plant ingredients
EP2349281A1 (en) 2008-10-30 2011-08-03 Hyben Vital Licens ApS Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition
DK177605B1 (en) 2010-03-16 2013-11-18 Hyben Vital Licens Aps Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis
EP2389816A1 (en) 2010-05-25 2011-11-30 Nestec S.A. Synergistic antioxidant composition
MX2012015059A (es) * 2010-06-25 2013-04-03 Horphag Res Ip Pre Ltd Composicion para mejorar el bienestar sexual.
TWI558403B (zh) * 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
JP6339426B2 (ja) * 2014-06-30 2018-06-06 株式会社ファンケル グリセロ糖脂質を含有する組成物の製造方法及びグリセロ糖脂質含有組成物
SG11201811595SA (en) 2016-06-27 2019-01-30 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
CN106983763B (zh) * 2017-04-25 2021-04-20 中国海洋大学 单半乳糖基二酰基甘油酯及其制备方法与用途
CN110201026B (zh) * 2019-07-15 2021-09-24 青岛农业大学 一种非抗生素型结肠炎修复制剂
KR102780726B1 (ko) * 2022-12-30 2025-03-13 주식회사 미래생명자원 테트라셀미스 츄이로부터 분리한 신규 화합물 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271270A (ja) 1992-03-27 1993-10-19 Nippon Paper Ind Co Ltd 糖ーグリセロール誘導体とその合成法
JP3298723B2 (ja) * 1993-03-30 2002-07-08 武田食品工業株式会社 発癌プロモーション抑制組成物
WO1994024984A2 (en) 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
JPH07149786A (ja) 1993-11-26 1995-06-13 Sagami Chem Res Center グリセロ糖脂質及び発癌プロモーター阻害剤
CA2142153A1 (en) 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
DE19634021A1 (de) 1996-08-23 1998-02-26 Beiersdorf Ag Antiadhäsive Glycoglycerolipide
DE19634019A1 (de) * 1996-08-23 1998-02-26 Beiersdorf Ag Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
DE19700774A1 (de) 1997-01-13 1998-07-16 Hoechst Ag Antiadhäsive Sulfatid-Mimetika
US6024960A (en) * 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis

Also Published As

Publication number Publication date
AU2002366210A1 (en) 2003-06-10
US20050049205A1 (en) 2005-03-03
EP1453844B1 (en) 2013-11-20
US20030139350A1 (en) 2003-07-24
WO2003043613A2 (en) 2003-05-30
EP1453844A2 (en) 2004-09-08
JP2010215660A (ja) 2010-09-30
CN1606563A (zh) 2005-04-13
WO2003043613A3 (en) 2004-03-25
NO334587B1 (no) 2014-04-14
JP2005513023A (ja) 2005-05-12
CN100469784C (zh) 2009-03-18
US7084122B2 (en) 2006-08-01
PL213644B1 (pl) 2013-04-30
NO20042112L (no) 2004-07-09
PL393941A1 (pl) 2011-06-20
JP4716655B2 (ja) 2011-07-06
AU2002366210A8 (en) 2003-06-10
PL370888A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
NO20042112L (no) Anvendelse av glycosider av mono- og diacylglycerol som anti-inflammatoriske midler.
DK1438306T3 (da) Derivater af UK-2A
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
DK1390377T3 (da) Ny krystalform af azithromycin
NO20041339L (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
NO20033969L (no) Triazolpyridiner som anti-inflammatoriske midler
NO20035087D0 (no) Anvendelse av HMG fragment som anti-inflammatoriske midler
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
DK1451143T3 (da) Fremgangsmåder til fremstilling af O-desmethylvenlafaxin
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
DK1335725T3 (da) Anvendelse af CCI-779 som et antineoplastisk middel
DK1307181T3 (da) Hidtil ukendte sammensætninger af minoxidil
PT1250321E (pt) Composicao de gliburida
CY2009001I1 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
DK1073416T3 (da) Anvendelse af NO som anti-inflammatorisk middel
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
PT1372937E (pt) Moldes de sopragem de dupla cavidade de múltiplas gotas
DK1263717T3 (da) Fremgangsmåde til fremstilling af methionin
FR2822853B1 (fr) Preaparation de (mono) cristaux
DE60117938D1 (de) Vorspannen von Bauteilen
NO20014753D0 (no) C(10)-karbonatsubstituerte taksaner som antitumormidler
IS5821A (is) Kristalluð form af ósanetant
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
NO20014755D0 (no) C(7)-karbonatsubstituerte taksaner som antitumormidler
NO20020524D0 (no) Stabiliserte organisk-peroksid sammensetninger